Dual treatment of acromegaly and hormone-receptor-positive breast cancer with tamoxifen: a case report
ConclusionThis case highlights the dual benefit of tamoxifen therapy in the treatment of hormone-receptor-positive breast cancer and acromegaly. Unlike anastrozole, tamoxifen has the benefit of lowering insulin-like growth factor 1 levels, which underscores its advantage in reducing adverse musculoskeletal symptoms during the treatment of hormone-receptor-positive breast cancer. We offer the first reported use of tamoxifen monotherapy for the successful treatment of acromegaly and hormone-receptor-positive breast cancer. While tamoxifen may offer an additional, oral option for acromegaly patients who do not respond to or tolerate conventional growth-hormone-lowering therapy, additional studies are necessary.
Source: Journal of Medical Case Reports - Category: General Medicine Source Type: research
More News: Acromegaly | Arimidex | Breast Cancer | Cancer | Cancer & Oncology | Endocrine Therapy | General Medicine | Hormones | Insulin | Oral Cancer | Study | Tamoxifen